|Publication number||US5589369 A|
|Application number||US 08/252,048|
|Publication date||Dec 31, 1996|
|Filing date||May 31, 1994|
|Priority date||Feb 11, 1992|
|Also published as||CA2128862A1, CA2128862C, DE69333082D1, DE69333082T2, EP0626012A1, EP0626012A4, EP0626012B1, WO1993016177A1|
|Publication number||08252048, 252048, US 5589369 A, US 5589369A, US-A-5589369, US5589369 A, US5589369A|
|Inventors||Jonathan G. Seidman, Aya Jakobovits|
|Original Assignee||Cell Genesys Inc., The President And Fellows Of Harvard College|
|Export Citation||BiBTeX, EndNote, RefMan|
|Non-Patent Citations (18), Referenced by (239), Classifications (23), Legal Events (6)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This is a continuation of application Ser. No. 07/833,992 filed Feb. 11, 1992, now abandoned.
The field of this invention is directed targeting of genes in viable cells.
There are continuing advances in the ability to modify cells. One of the most exciting areas for the treatment of genetic diseases is gene therapy. In those situations where cells can be isolated, which are relatively long-lived and can be grown in culture and expanded, one has the opportunity to isolate such cells from a host, either the diseased host or an allogeneic host. The cells may then be grown in culture, expanded, and modified by homologous recombination, and the modified cells restored to the host.
In other situations, one wishes to produce products which are exogenous to the host. In this situation, one may modify embryonic stem cells, add them to a blastocyst, and then produce a chimeric host. This chimeric host may then be mated and the progeny either used as heterozygous mutants or further mated to produce homozygous mutants. By providing for appropriate changes in the embryonic cells, one can produce various human proteins in bovine milk and the like.
Alternatively, one may wish to change the nature or characteristics of a product of a host, such as meat, vegetable oils, size, or the like. In many cases, homologous recombination will be required with both genes, since the host will be diploid. This means that one must go through an extensive number of steps in first modifying one gene, ensuring that the proper modification has occurred, then using the modified cells to repeat the process and modify the second gene. Even where the modification is a knock-out, namely introduction of an interfering sequence and/or deletion into the target locus, the process can be time-consuming and labor-intensive. There is, therefore, substantial interest in being able to develop techniques which allow for improvements in the efficiency of achieving genetic modifications at target loci.
Procedures for the modification of ES cells and detection of the modified cells may be found in Mortensen, et al., Proc. Natl. Acad. Sci. (USA) 88, 7036-7040 (1991). Paludan, et al., Gene 85, 421-426 (1989) reports enhanced resistance of cells comprising multiple neo genes. Spontaneous production of homozygous cells from heterozygous cultured cells have been reported by Nelson, et al., Mol. Cell. Biol. 9, 1284-1288 (1989); Potter, et al., Proc. Natl. Acad. Sci. (USA). 84, 1634-1637 (1987); Rajan, et al., J. Immunol, 145, 1598-1602 (1990) and Campbell, et al., Mol. Cell. Biol. 1, 336-346 (1981).
Homogenotization of gene targeting events is achieved by introducing DNA into cells, where the DNA has homology to a target locus and contains a marker gene. Cells undergoing homologous recombination are selected and subjected to elevated levels of the selection agent. Cells are then selected which have undergone gene conversion, where the mutant is now homozygous for the modification. The selective gene is normally one that imparts drug resistance and is normally incapable of amplification.
Mutant cells which are homozygous at a targeted locus are produced by introducing DNA into the cells, where the DNA has homology to the target locus and includes a marker gene, allowing for selection of cells comprising the integrated construct. The cells are then screened for homologous recombinants. The homologous integrants are exposed to elevated levels of the marker gene, selecting for cells which have multiple copies of the selective agent by other than amplification. The cells are then analyzed for homozygosity at the target locus.
Various constructs can be prepared for homologous recombination at a target locus. Usually, the construct will include at least 50 bp of sequence homologous with the target locus and not more than 500 Kbp. The marker gene will normally be flanked on both sides by homologous sequences.
Various marker genes may be employed, which have the following characteristics. The marker gene is not amplifiable in that with increasing concentrations of the selective agent, one does not detect spontaneous events in which the gene has undergone tandem replication. The selective agent should not be extremely toxic, so that minor variations in concentration should not have significant effects on the viability of cells. Thus, one can provide for easy gradations in change of concentration of the selective agent so as to specifically select for cells having increased resistance to the selective agent. Gradations will be generally such that upon plating the heterozygous mutant at higher concentrations of the selective agent, there will colony forming efficiency of from about 1 in 10-105.
The transcriptional initiation region for the marker gene may be any convenient region, either inducible or constitutive. By providing for an inducible transcription initiation region, the marker gene may be silent when the cells are introduced into a host, where the inducible agent is absent or the gene is turned on upon being introduced into a host or upon maturation and differentiation of the cells. Inducibility may be as a result of temperature, specific compounds, etc. A wide variety of promoters have been described in the literature, which are constitutive or inducible, where induction may be the result of temperature, inducing agents, any specific cell type or specific level of maturation. Also, a number of viral promoters are known, which may also find use. Promoters of interest include the β-actin promoter, SV40 early and late promoters, phosphoglycerate kinase promoter ("PGK"), immunoglobulin gene promoter, thymidine kinase promoter, human cytomegalovirus promoter and the Friend spleen focus-forming virus promoter. The promoters may or may not be associated with enhancers, where the enhancers may be naturally-associated with the particular promoter or associated with a different promoter.
A termination region will be present, where the termination region may be naturally-associated with the marker gene or may be derived from a different gene. For the most part, the termination regions are not critical and a wide variety of termination regions may be employed without adversely affecting expression or the utility of the marker gene.
DNA constructs will be prepared for integration into the target locus. The construct will comprise the marker gene, with its appropriate transcriptional and translational initiation and termination regulatory regions, flanked by regions of homology with the target locus. The integration of the subject marker gene at the target locus may interfere with functional expression in a variety of ways, preferably by insertion into the coding region or an exon of the target locus, but may also interfere by insertion into an intron where the construct has a splice-acceptor site adjacent to the marker gene, as to truncate the target locus and prevent expression of a functional protein. If one wishes, rather than providing for an independent transcriptional initiation region as part of the construct, one could provide for integration into the target locus at a site which introduces the marker gene under the transcriptional control of the transcription initiation region of the target gene, e.g. into an intron where the construct has at the 5' terminus of the marker gene a splice-acceptor site, or into an exon resulting in fusion of the reading frames of the target and marker genes. The significant factor is that integration of the marker gene at the target locus results in inactivation of the target gene.
The regions of homology with the target locus will usually be at least about 50 bp, more usually at least about 150 bp and may be as high as 500 Kbp, usually not more than about 20 Kbp, preferably not more than about 10 Kbp. Usually, there will be at least about 20, more usually at least about 50 bp of homology 5' and 3' of the marker gene. Various considerations will be involved in the extent of homology, such as the size of the target locus, availability of sequences, relative efficiency of double cross-over events at the target locus, similarity of the target sequence with other sequences, and the like.
The region(s) of homology may include mutations, where mutations may further inactivate the target gene, in providing for a frame shift, or changing a key amino acid, or the mutation may correct a dysfunctional allele, etc. Usually, the mutation will be a subtle change, not exceeding about 5% of the homologous flanking sequences, usually fewer then 50 bp. Where mutation of a gene is desired, the marker gene may be inserted into an intron, so as to be excised from the target gene upon transcription.
The construct will be prepared in accordance with known ways, where various fragments will be brought together, introduced into appropriate vectors, cloned, analyzed and then manipulated further until the desired construct has been made. Various modifications may be made to the sequence, to allow for restriction analysis, excision, identification of probes, or the like. Silent mutations may be introduced, as desired. At various stages, restriction analysis, sequencing, amplification with the polymerase chain reaction, primer repair, in vitro mutagenesis, or the like may be employed.
The construct will usually be prepared using a bacterial vector, including a procaryotic replication system, e.g. an origin recognizable by E. coli, where at each stage, the construct may be cloned and analyzed. A marker, the same as or different from the marker to be used for insertion, may be employed, where the procaryotic marker is usually removed prior to introduction into the target cell. Once the vector containing the construct has been completed, it may be further manipulated by deletion of the bacterial sequences, linearization, introducing a short deletion in the homologous sequence, generally not exceeding about 500 bp, generally below about 20% of the homologous sequence, usually in the range of about 50-300 bp. After final manipulation, the construct is ready to be introduced into the cell.
A wide variety of eukaryotic target host cells may be employed, normally cells from vertebrates, more particularly, mammals, desirably domestic animals or primates, particularly humans. The cells which may be subjected to transformation may be any mammalian cells of interest, which may find use in cell therapy, research, interaction with other cells in vitro or the like. Cells of particular interest include, among other lineages, stem cells, e.g. hematopoietic stem cells, embryonic stem cells, etc., the islets of Langerhans, adrenal medulla cells which may secrete dopamine, osteoblasts, osteoclasts, epithelial cells, endothelial cells, leukocytes, e.g. B- and T-lymphocytes, myelomonocytic cells, etc., neurons, glial cells, ganglion cells, retinal cells, liver cells, e.g. hepatocytes, bone marrow cells, keratinocytes, hair follicle cells, and myoblast (muscle) cells.
For embryonic stem cells, an embryonic stem cell line may be employed or embryonic stem cells may be obtained freshly from a host. The cells may be grown on an appropriate fibroblast fetal layer or grown in the presence of leukemia inhibiting factor (LIF) and then used. The embryonic stem cells may be injected into a blastocyst to provide a chimeric animal.
Upstream and/or downstream from the target gene construct may be a gene which provides for identification of whether a double cross-over has occurred. For this purpose, the herpes simplex virus thymidine kinase ("HSV-tk") gene may be employed, since the presence of the thymidine kinase gene may be detected by the use of nucleoside analogs, such as acyclovir or gancyclovir, for their cytotoxic effects on cells that contain a functional HSV-tk gene. The resistance to these nucleoside analogs indicates the absence of the thymidine kinase gene and, is therefore, indicative that a double cross-over event has occurred and -thus homologous recombination has also occurred.
Various techniques may be employed for introduction of the construct into the host cell. Techniques which may be used include calcium phosphate/DNA coprecipitates, micro-injection of DNA into the cell, electroporation, lipofection, bacterial protoplast fusion with intact cells, transfection or the like. The DNA may be single- or double-stranded, linear or circular, relaxed or supercoiled DNA. For various techniques for transforming mammalian cells, see Keown, et al., Meth. in Immun. 185, 527-537 (1990). The cells may then be grown in appropriately-selected medium to identify cells providing the appropriate integration. Those cells which show the desired phenotype may then be further analyzed by restriction analysis, electrophoresis, Southern analysis, polymerase chain reaction, or the like. By identifying fragments which show the appropriate insertion at the target gene site, one can identify cells in which homologous recombination has occurred to inactivate or otherwise modify one of the two copies of the target gene.
The heterozygote cells containing the integrated marker gene may then be expanded in an appropriate culture medium over an extended period of time, usually at least one week and up to six weeks or more. The cells may then be plated, and individual colonies selected at varying concentrations of the drug to which the marker gene imparts resistance. For example, with neomycin resistance, depending upon the nature of the cell, the concentration of G418 may vary from about 0.5-4 mg/ml, more usually from about 0.5-2.5 mg/ml. The surviving colonies may then be screened to establish that the functional endogenous gene is absent or has been properly mutated. As described above, various techniques may be used for analyzing for the presence of homozygosity of the mutant. The resulting homozygote will have two copies of the same gene on different chromosomes, normally including the marker gene. The cell usually will otherwise be free of the construct.
The subject invention may find wide application, where one wishes to inactivate a particular gene or introduce an alteration into a gene at a target locus. Genes of interest include a variety of surface membrane protein genes. One area of interest is reduction in the expression of major histocompatibility complex antigens, Class I and/or II, or any of the individual groups, such as A, B, C, DP, DQ and DR. For knocking out Class I, one may provide for integration into the β2-microglobulin gene. For Class II antigens, it may be sufficient to knock out the DR genes. Thus, one may reduce the immunologic response associated with the presence of foreign MHC antigens, when such antigens are introduced into a host. Alternatively, one may wish to inhibit expression of the host gene when one is introducing an exogenous immunoglobulin gene, e.g. knocking out the host immunoglobulin locus, when introducing an exogenous locus. Other genes of interest include those affecting MHC expression or other components of the antigen presentation machinery of the cell which ultimately affect immunogenicity.
One may also use the subject method to study various metabolic processes, to identify the effect of the absence of a particular genetic capability, and the like. In this manner, one may be able to identify the role of particular oncogenes, the effect of regulatory proteins, the roles of enzymes, the presence of alternative pathways, and the like.
One may also use the subject methodology for introducing mutations into dysfunctional alleles, so as to cure genetic defects, particularly where subtle changes are involved such as those involving fewer than about 50 bp, frequently fewer than about 10 bp. Thus, one could modify stem cells, such as hematopoietic stem cells, to cure diseases such as sickle cell anemia, β-thalassemia, hemophelia, etc., targeting genes for gene therapy which include genes for β-globin, enzymes of erythrocyte metabolism, the complement system, coagulation factors, dystrophin, enzymes of carbohydrate, lipid, amino acid, steroid and purine and pyrimidine metabolism, transport proteins, e.g., cystic fibrosis transmembrane regulator, and the like.
The modified embryonic stem cells may be used to produce chimeric non-human mammals by injecting he homogenotized embryonic stem cells into a blastocyst and then brought to term in a female host mammal in accordance with conventional techniques. Heterozygous progeny may then be screened for the presence of the alteration at the site of the target locus, using PCR, Southern blotting or the like. After mating with a wild-type host of the same species, the resulting chimeric progeny may then be cross-mated to achieve homozygous hosts. The homozygous hosts may have a variety of alterations, where the gene at the target locus may be made non-functional, may be retained as functional, but altered, or may be retained and additional genetic capability provided, where the additional capability may be coregulated by concomitant transcription with the gene at the target locus.
The mammalian host will have target loci comprising alleles which should be at least substantially identical, in having the marker gene integrated at the same position at both alleles. In addition, any alterations as a result of the homologous recombination in the first step should also be present in both alleles. In this way a "double knockout," symmetrical integration, which may include one or more alterations at the target locus, or the like may be achieved.
The homozygotes may be subject to further genetic modification. For example, one may wish to introduce additional genetic capability into the homozygotic hosts, where the endogenous alleles have been made nonfunctional, to substitute, replace or provide different genetic capability to the host. For example, one may wish to produce human immunoglobulins in small host, such as a mouse or rabbit. By first knocking out the endogenous genes encoding for the light and heavy chains of the immunoglobulins, one can then introduce genes from the human loci, which genes encode for the human light and heavy chains and are capable of rearrangement in response to immunization of the host to produce human immunoglobulin proteins. For example, one may knockout the J regions, which prevents expression of the immunoglobulin subunits.
One may wish to remove the marker gene after homogenotization. By introducing a construct comprising substantially the same homologous DNA, possibly extended sequences, having the marker gene portion of the original construct deleted, one may be able to obtain homologous recombination with the target locus. By using a combination of marker genes for integration, one providing positive selection and the other negative selection, in the removal step, one would select against the cells retaining the marker genes. Convenient marker genes for negative selection include the herpes simplex virus thymidine kinase gene, whose presence results in sensitivity to nucleoside analogs, such as acyclovir and gancyclovir.
In bovine or ovine hosts, one may wish to replace the bovine or ovine protein with a human protein. In domestic animals, one may wish to introduce alterations which result in improved products or growth of the host. Where domestic animals are prone to diseases as a result of particular alleles, one may alter the alleles to reduce the susceptibility to the disease.
Hosts of interest include, primates other than man, ovine, bovine, equine, canine, feline, lagomorpha, murine, etc.
The following examples are offered by way of illustration and not by way of limitation.
Four separate genes, G-protein subunits αi2 and αi3, T-cell receptor (TCR)-α, β-cardiac myosin heavy chain (MYHC-B) were targeted using positive/negative selection (Mansour, et al., Nature 336, 348-352 ). In each case, a targeting construct was made containing the neomycin-resistance gene (neo) driven by the promoter region of phosphoglycerate kinase (PGK) gene. The PGK-neo sequence interrupted an exon creating a detectable change in the gene's restriction enzyme digestion pattern.
In each case PGK-TK phosphoglycerate kinase promoterthymidine kinase gene) was inserted outside the regions of homology. A) The production of the αi2 target construct has been described previously in Mortensen, et al., Proc. Natl. Acad. Sci. (USA) 88, 7036-7040 (1991). B) αi2 gene clone was isolated as described for the αi2 gene. A Hind III-Sal I fragment was subcloned into Bluescript SK (+) (Stratagene). The construct contained the PGK-neo gene interrupting exon 1 at an Nco I site at the translational start ATG. C) A 5.6 Kbp fragment of the murine TCR-α gene containing all 4 constant-region exons was subcloned from genomic clone λ*1.2 into Bluescript SKII (+) (Ausubel, et al., Curr. Proto. in Mol. Biol. [John Wiley and Sons, New York, 1988]). The fragment extends from an artificial EcoRI site, 5' of the Xba I site to the XhoI site. The EcoRI site between exons 3 and 4 was deleted by digestion with EcoRI, blunting with Klenow and subsequent ligation. The first constant-region exon was interrupted at a unique EcoRV site by the insertion of PGK-neo. D) A 7.5 Kbp (SalI-EcoRV) portion of the Myhc-B gene extending from approximately exon 10 to approximately exon 24 was cloned from a Balb/c genomic library (Clontech), identity was confirmed by sequencing. A targeting construct was made by interrupting the gene at a unique Nde I site in exon 14.
ES cells (line CCE obtained from E. Robertson, Columbia University or CC1.2 obtained from A. Bradley, Baylor University) were cultured, transfected and screened for homologous recombination as previously described (Mortensen, supra ). Several cell lines identified as heterozygous for homologous recombination were expanded for 14-28 days. Cell lines were then plated, cultured for 24 hours and then selected at varying concentrations of G418. DNA from the surviving clones was analyzed by Southern blot for absence of the endogenous gene.
TABLE 1__________________________________________________________________________Loss of heterozygosity in ES cell lines [G418] (mg/ml) 1.0-1.5 2.0Gene Cell No. Cells No. of % Homozygote No. of % Homozygote(Parent Line) Line Plated* Colonies (No. Analyzed) Colonies (No. Analyzed)__________________________________________________________________________α12 (CCE) 17E10 2 × 104 23 100% (21) 2 0% (2) 18D3 2 × 104 175 12% (26) 40 ND#α13 (CC1.2) 32-32 1 × 105 100 53% (17) 17 88% (17) 32-28 1 × 106 27 4% (28) 0TCR-α (CCE) 1A4 5 × 105 37 43% (23) 9 44% (9)Myhc-b (CC1.2) 6-6 5 × 105 54 24% (54) 6-22 5 × 105 76 7% (76) 2 50% (2)__________________________________________________________________________ *Efficiency of plating 40-80% # ND - not determined
Southern blot analysis of DNA from the clones isolated in high concentrations of G418 was carried out. DNA was fractionated on 1% agarose gels, transferred to Genescreen and hybridized as previously described (Ausubel, supra ). In each case, a band was observed for the homologous recombination product, for αi2, a 13.6 Kb band, for αi3 a 6.5 band, for TCR-α, a 2.0 band and for Myhc-B, a 7.1 band. The β-cardiac myosin probe cross-reacted with the Myhc-A (α-cardiac myosin heavy chain), gene resulting in 2 bands being present in each lane.
To determine the frequency of homozygous mutant ES cells surviving high G418, 4 individual heterozygous subclones were isolated by plating trypsin-dispersed 17E10 cells at high dilution. Each of these subclones and the original 17E10 clones were plated 5×105 cells/100 mm plate, selected at high G418 levels and the surviving clones analyzed as in Table 1. Plating efficiency without G418 was 42%.
TABLE 2__________________________________________________________________________Frequency of homozygous mutant ES cells surviving high G418[G418] (mg/ml)1.0 2.0Subclone of No. % Homozygote No. % Homozygote Apparent No.17E10 Colonies (No. Analyzed) Colonies (No. Analyzed) of Colonies*__________________________________________________________________________1 143 75% (20) 28 94% (18) 114.42 152 92% (24) 52 95% (19) 139.33 44 22% (9) 0 9.84 40 95% (21) 5 100% (4) 38.1Average 75.4†±Std. Dev. ±61.4__________________________________________________________________________ *Calculated from (fraction of homozygotes at 1 mg/ml) × (total no. of colonies) †An estimated rate of mutation per cell generation of 1.3 × 10-5 was calculated from the number of generations since recloning (assuming a generation time of 14.2 hours2 and the fraction of homozygotes [(average No. of colonies)/((No. of cells plated) × (plating efficiency))] according to the equation rate = (fraction of homozygotes)/(No. of generations since cloning). Cells were cultured for 16 days (27 generations) after plating at high dilution. Mass cultures from the original clone were selected in parallel giving 241, 261, 228, and 262 colonies per 100 mm plate containing >90% homozygotes (18 analyzed).
A 6.1-Kb EcoRI fragment, containing the mouse immunoglobulin heavy chain J region genes and flanking sequences, cloned from a Balb/c mouse embryo genomic library and inserted into pUC18 (pJH), was digested with XhoI and NaeI to delete an about 2.3 kbp fragment containing the four J genes (see Chart 2A). An about 1.1 kbp XhoI-BamHI fragment, blunted at the BamHI site, containing a neomycin resistance gene driven by the Herpes simplex virus thymidine kinase gene (HSV-tk) promoter and polyoma enhancer was isolated from pMClNeo (Thomas and Capecchi, Cell, 51, 503-512, 1987). This fragment was inserted into the XhoI-NaeI deleted pJH to form the inactivation vector (pmHδJ, see Chart 2B), in which the transcriptional orientation of the neomycin and the heavy chain genes is the same. This plasmid was linearized by NdeI digestion before transfection to ES cells. The sequences driving the homologous recombination event are about 2.8 kbp and about 1.1 kbp fragments, located 5' and 3' to the neomycin gene, respectively.
Culturing, Electroporation, and Selection of ES cells
The ES cell line E14TG2a (Koller and Smithies, 1989, PNAS, USA, 86, 8932-8935) was cultured on mitomycin C-treated embryonic fibroblast feeder layers as described (Koller and Smithies, 1989, PNAS USA, 86, 8932-8935). ES cells were trypsinized, resuspended in HBS buffer (pH 7.05; 137 mM NaCl, 5 mM KCl, 2 mM CaCl2, 0.7 mM Na2 HPO4, 21 mM HEPES pH 7.1) at a concentration of 2×107 /ml and electroporated in the presence of 50 μg/ml of the linearized inactivation vector. Electroporation was carried out with a BioRad Gene Pulser using 240 volts and 500 μF capacitance. 5×106 electroporated cells were plated onto mitomycin C-treated fibroblasts in 100 mm dishes in the presence of Dulbecco's modified Eagle's media (DMEM) supplemented with 15% fetal bovine serum and 0.1 mM 2-mercaptoethanol. The media was replaced 24 hr after electroporation with media containing 200μg/ml G418. G418-resistant ES colonies resulting 12-14 days after electroporation were picked with drawn out capillary pipettes for analysis using the polymerase chain reaction (PCR). Half of each picked colony was transferred to an individual well of a 24-well plate, already seeded with mitomycin C-treated feeder cells. The other halves, combined in pools of four, were transferred to Eppendorf tubes containing 0.3 ml of PBS and cell lysates were prepared for PCR analysis as described by Joyner et al (Nature, 338:153-155, 1989). The PCR reaction included 5-20 μl of the cell lysate, 1 μM of each primer, 1.5 u of Taq polymerase and 200 μM of dNTPs. The PCR amplification employed 45 cycles using a thermal cycler (Perkins-Elmer Cetus), with 1 min melt at 94° C. 2 min annealing at 55° C., and 3 min. extension at 72° C. The two priming oligonucleotides are ACGGTATCGCCGCTCCCGAT (SEQ. ID NO: 1) and AGTCACTGTAAAGACTTCGGGTA, (SEQ ID NO: 2) which correspond respectively to about 120 bases 5' of the BamHI site of the neomycin gene, and to the sequences located in the mouse heavy chain gene, about 160 bases 3' of the insertion site. Successful homologous recombination gives rise to an about 1.4 kbp fragment. 20μl of the reaction mixture is electrophoresed on 1% agarose gels, stained with ethidium bromide and transferred to nylon membranes (Gene Screen). Filters were probed with a 32 P-labelled ECORI-PstI about 1.4 kbp fragment located in the mouse heavy chain, 3' of the insertion site (see Chart 2). For further analysis, genomic DNA was prepared from ES cells, digested with restriction enzymes as recommended by the manufacturers, and fragments were separated on 1% agarose gels. DNA was transferred to nylon membranes (Gene Screen) and probed with the 32 P-labelled fragment as described above.
Analysis of G418-resistant ES colonies
In the first experiment, PCR analysis of the pooled colonies detected one positive PCR signal of the expected size (about 1.4 kbp) out of 34 pools representing 136 G418-resistant colonies. The four individual colonies that had contributed to this positive pool were analyzed individually by PCR, and a positive clone, ES33D5, was identified. Similar analysis of 540 G418-resistant colonies obtained in the second experiment yielded 4 additional positive clones (ES41-1), ES61-1, ES65-1, ES110-1).
In order to verify the targeting disruption of one copy of the J genes, (the gene is autosomal and thus present in two copies), the PCR positive clones were expanded and genomic DNA was prepared, digested with HindIII or with SacI and analyzed by Southern analysis as described using the EcoRI-PstI probe.
The replacement of the J genes by insertion of the neomycin gene by an homologous recombination event results in an HindIII fragment, detectable with the EcORI-PstI probe, which is about 1.9 kbp longer than the equivalent fragment in the native locus, due to the loss of two HindIII sites located in the deleted J gene region (see Chart 2C). Southern analysis of each of the 5 positive clones by HindIII digestion gave a pattern which indicated that one of the two copies of the heavy chain J genes had been disrupted. Three labeled fragments were detected: one fragment (about 760 bp), identical in size to that present in untreated cells at the same intensity, one fragment (about 2.3 kbp) identical in size to that present in untreated cells, but of decreased intensity in the PCR positive clone, and an additional fragment about 4.2 kbp, the size predicted for an homologous recombination event, present only in the PCR-positive clones. Similarly, the replacement of the J genes by the neomycin gene by an homologous recombination event results in a loss of one SacI site and the appearance of a fragment, detectable with the EcoRI-pStI probe, which is about 570 bp smaller than the equivalent fragment in the native locus (see Chart 2C). Southern analysis of the clones by SacI digestion gave the expected pattern of one native and one targeted allele: about 4.0 kbp fragment, identical in size to that detected in untreated cells, but of decreased intensity in the 5 positive clones, and an additional fragment of about 3.4 kbp, the size predicted for a targeted homologous recombination event, present only in the identified clones. Rehybridization of the Southern blots with a probe for the neomycin gene shows that only the 4.2 kbp and 3.4 kbp fragments, resulting from the HindIII and the SacI digestion, respectively, hybridized to the probe as predicted by the targeting event.
Injection of targeted ES cells into mouse blastocysts and generation of chimeric offsprings
Mice were purchased from Jackson Laboratories (Bar Harbor, Me). Three and a half day old C57BL/6 blastocysts were obtained from 4-5 week old superovulated females as described by Koller et al. 1989 supra. ES cells were trypsinized, washed once with fresh DMEM media and diluted to about 1×106 /ml in M2 media. About 5 μl of cells were added to a 150 μl droplet of M2 media, under paraffin oil, containing the blastocysts. Ten to fifteen cells were injected into the blastocoel of each blastocyst. Six to nine ES cell-containing blastocysts were returned to each uterine horn of C57BL/6×DBA F1 pseudopregnant females mated 2.5 days previously with vasectomized males. Pups derived from the injected blastocysts were generally born 16-18 days later. The contribution of the ES cells to the offspring was judged visually by examination of the coat color of the pups. The blastocysts were obtained from C57BL/6 mice, which are solid black in color. The ES cell line E14TG2a, the parental line from which the targeted cell lines were derived, was isolated from 129/01a mice. This mouse strain is cream in color, the combined effect of three color genes, the dominant Aw allele at the agouti locus, the recessive pink-eyed-diluted allele at the p locus and the recessive Cch allele at the C locus. Offspring in which the ES cells participated in the formation of the animal had coats containing brown and cream hair. The ES cell line ES41-1 carrying inactivated mouse immunoglobulin heavy chain, was injected into C57BL/6 mouse blastocysts as described above. Six out of the 18 surviving pups had a high degree of coat color chimerism (70-90%). PCR analysis of DNA isolated from chimeric newborn pups from a female implanted with blastocysts injected with the inactivated ES cells, indicated that the mutated immunoglobulin heavy chain locus is present in a variety of organs such as spleen, thymus, kidney, liver, brain and skin.
Homogenotization of inactivated Ig heavy-chain J genes in ES cells
Heavy-chain J gene-targeted ES 110-1 cell line was plated on feeder cells at the density of 5×103 cells per 100 mm plate in the presence of 1400 μg/ml of G418. Seven of the surviving colonies were expanded, genomic DNA was prepared and anlayzed by Southern analysis for the absence of endogenous Ig heavy-chain J gene. Southern analysis by Sac I digestion indicated that one of the clones, ES DK207, had lost the native Ig heavy chain locus. Hybridization of the same blot with an Xho I-Nae I probe, which spans the whole J gene region, did not detect any fragments in the ES DK207 genome, further indicating the loss of the native Ig heavy-chain allele.
Generation of chimeric mice carrying homogenotized heavy-chain targeted B cells
ES DK207 cells were injected into mouse blastocysts and chimeric mice were generated as described above. Then chimeric mice were obtained, seven of which had 40-70% coat color chimerism, indicating the ES cell contribution to these mice.
The mice were used to determine the effect of the deletion of the J genes from both heavy-chain alleles on the capability of the B cells to differentiate and express antibodies. Analysis of peripheral blood lymphocytes derived from one of these chimeras, DK334-1, indicated that about 10% of the lymphocytes are derived from the mouse strain from which the ES cells originated, namely the 129Sv\Ola strain. This was determined with Ly9a antibodies which bind to cells from strain 129, but not cells from strain C57B/6. The absence of mature B cells originating from strain 129 was established by demonstrating by means of fluorescence activated cell sorting that the lymphocytes from strain 129 lacked the surface antigens CD45Rbright and IgMa. These results support the conclusion that due to the deletion of the J region inboth alleles of the Ig heavy chain, B cell development is inhibited in lymphocytes derived from ES DK207.
It is evident from the above results, that the subject methodology provides for an effective efficient way to produce homozygosity in two or more alleles in a host, where one wishes to change the nature of one or more alleles. In this manner, one may knock out the two alleles present in a diploid host, mutate two alleles, so as to have the same sequence, while still retaining a sufficiently high frequency to allow for isolation of the desired homozygotes. The subject method can be used in a wide variety of applications, in transgenic animals, modification of the surface proteins present on a host cell, so as to reduce or enhance immunogenicity, and the like.
All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 2(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:ACGGTATCGCCGCTCCCGAT20(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:AGTCACTGTAAAGACTTCGGGTA23__________________________________________________________________________
|1||*||Blomberg et al (1982) Proced. Natl. Acad. Sci. 79, 530 533.|
|2||Blomberg et al (1982) Proced. Natl. Acad. Sci. 79, 530-533.|
|3||*||Campbell and Worton (1981) Mo. Cell. Bio. 1:336 346. Segregation of recessive phenotypes on somatic cell hybrids: Role of mitoic recombination, gene inactivation and chromosomal non disjunction.|
|4||Campbell and Worton (1981) Mo. Cell. Bio. 1:336-346. Segregation of recessive phenotypes on somatic cell hybrids: Role of mitoic recombination, gene inactivation and chromosomal non-disjunction.|
|5||*||F. Nelson, et al. (1989) M. C. Bio. 9:1284 1288. Mitotic recombination is responsible for the loss of heterozygosity in cultured murine cell lines.|
|6||F. Nelson, et al. (1989) M. C. Bio. 9:1284-1288. Mitotic recombination is responsible for the loss of heterozygosity in cultured murine cell lines.|
|7||*||K. Paludin, et al. (1989) Gene 85:421 426. Gradauted resistance to G418 leads to differential selection of culture mammalian cells expressing the neo gene.|
|8||K. Paludin, et al. (1989) Gene 85:421-426. Gradauted resistance to G418 leads to differential selection of culture mammalian cells expressing the neo gene.|
|9||*||Paluean et al (1989) Gene 85, 421 426.|
|10||Paluean et al (1989) Gene 85, 421-426.|
|11||*||R. Mortenson, et al. (1991) P.N.A.S. 88:7036 7040. Embryonic stem cells lacking a functional inhibitory G protein subunit produced by gene targeting of both alleles.|
|12||R. Mortenson, et al. (1991) P.N.A.S. 88:7036-7040. Embryonic stem cells lacking a functional inhibitory G-protein subunit produced by gene targeting of both alleles.|
|13||*||T. Potter, et al. (1987) P.N.A.S. 84:1634 1637. Mitotic recombination between homologous chromosomes generates H 2 somatic cell variants in vitro.|
|14||T. Potter, et al. (1987) P.N.A.S. 84:1634-1637. Mitotic recombination between homologous chromosomes generates H-2 somatic cell variants in vitro.|
|15||*||T. Rajan, et al. (1990) J. Imm. 145:1598 1602. Rate and mechanism of generation of 2 microglobulin mutants from a heterozygous murine cell line.|
|16||T. Rajan, et al. (1990) J. Imm. 145:1598-1602. Rate and mechanism of generation of β2-microglobulin mutants from a heterozygous murine cell line.|
|17||*||Zijlstra et al (1989) Nature 342, 435 438.|
|18||Zijlstra et al (1989) Nature 342, 435-438.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5731181 *||Jun 17, 1996||Mar 24, 1998||Thomas Jefferson University||Chimeric mutational vectors having non-natural nucleotides|
|US5756325 *||Sep 9, 1996||May 26, 1998||Thomas Jefferson University||Compounds and methods for site directed mutations in eukaryotic cells|
|US5795972 *||Dec 2, 1997||Aug 18, 1998||Thomas Jefferson University||Chimeric mutational vectors having non-natural nucleotides|
|US5871984 *||Dec 2, 1997||Feb 16, 1999||Thomas Jefferson University||Compounds and methods for site directed mutations in eukaryotic cells|
|US5948653 *||Aug 13, 1997||Sep 7, 1999||Pati; Sushma||Sequence alterations using homologous recombination|
|US6074853 *||Aug 14, 1998||Jun 13, 2000||Sri||Sequence alterations using homologous recombination|
|US6200812||Apr 8, 1999||Mar 13, 2001||Sri International||Sequence alterations using homologous recombination|
|US6528313||Sep 6, 1994||Mar 4, 2003||Institut Pasteur||Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made|
|US6924146 *||Feb 20, 1998||Aug 2, 2005||Sigrid Wattler||Method of constructing vectors for homologous recombination directed mutagenesis|
|US7217699||Jan 3, 2001||May 15, 2007||Panagenic International, Inc.||Compositions comprising genome segments and methods of using the same|
|US7575893||Jan 23, 2004||Aug 18, 2009||Genentech, Inc.||Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture|
|US7777008||Jun 19, 2007||Aug 17, 2010||Tolerx, Inc.||ILT3 binding molecules and uses therefor|
|US7794713||Oct 28, 2005||Sep 14, 2010||Lpath, Inc.||Compositions and methods for the treatment and prevention of hyperproliferative diseases|
|US7807168||Apr 9, 2008||Oct 5, 2010||Vaccinex, Inc.||Selection of human TNFα specific antibodies|
|US7812135||Mar 27, 2006||Oct 12, 2010||Tolerrx, Inc.||GITR-binding antibodies|
|US7820161||May 4, 2000||Oct 26, 2010||Biogen Idec, Inc.||Treatment of autoimmune diseases|
|US7820165||Nov 21, 2006||Oct 26, 2010||Merck Serono, S.A.||Compositions and methods of producing hybrid antigen binding molecules and uses thereof|
|US7862812||Apr 6, 2007||Jan 4, 2011||Lpath, Inc.||Methods for decreasing immune response and treating immune conditions|
|US7914785||Mar 29, 2011||Bergen Teknologieverforing As||B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome|
|US7981418 *||Jul 19, 2011||Genentech, Inc.||Predicting response to a HER inhibitor|
|US8021865||Aug 12, 2008||Sep 20, 2011||Tmo Renewables Limited||Thermophilic micro-organisms for ethanol production|
|US8058406||Nov 15, 2011||Biogen Idec Ma Inc.||Composition comprising antibodies to LINGO or fragments thereof|
|US8128926||Mar 24, 2009||Mar 6, 2012||Biogen Idec Ma Inc.||Sp35 antibodies and uses thereof|
|US8138313||Jun 13, 2008||Mar 20, 2012||Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts||Treatment of tumors using specific anti-L1 antibody|
|US8143038||Mar 27, 2012||Tmo Renewables Limited||Thermophilic micro-organisms for ethanol production|
|US8158124||May 29, 2008||Apr 17, 2012||Lpath, Inc.||Compositions and methods for binding lysophosphatidic acid|
|US8222373||Jul 17, 2012||Lpath, Inc.||Humanized antibodies and compositions for binding sphingosine-1-phosphate|
|US8278421||Dec 13, 2006||Oct 2, 2012||Xoma Techolology Ltd.||Human antibodies specific for gastrin materials and methods|
|US8343928||Jul 7, 2006||Jan 1, 2013||Seattle Genetics, Inc.||Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus|
|US8361465||Jan 19, 2010||Jan 29, 2013||Lpath, Inc.||Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents|
|US8388967||Mar 5, 2013||Gitr, Inc.||Methods for inducing or enhancing an immune response by administering agonistic GITR-binding antibodies|
|US8401799||Jun 4, 2010||Mar 19, 2013||Lpath, Inc.||Antibody design using anti-lipid antibody crystal structures|
|US8425910||Apr 23, 2013||Biogen Idec Ma Inc.||Composition comprising antibodies to LINGO or fragments thereof|
|US8444970||Oct 26, 2007||May 21, 2013||Lpath, Inc.||Compositions and methods for treating ocular diseases and conditions|
|US8486687||Nov 5, 2009||Jul 16, 2013||Tmo Renewables Limited||Sporulation-deficient thermophilic microorganisms for the production of ethanol|
|US8486893||Jun 24, 2005||Jul 16, 2013||Biogen Idec Ma Inc.||Treatment of conditions involving demyelination|
|US8524454||Apr 5, 2007||Sep 3, 2013||The Research Foundation Of State University Of New York||Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency|
|US8541222 *||Jun 7, 2006||Sep 24, 2013||Tmo Renewables Limited||Modified microorganisms with inactivated lactate dehydrogenase gene|
|US8545843||Sep 20, 2010||Oct 1, 2013||Genentech, Inc.||Treatment of vasculitis|
|US8551476||Aug 17, 2007||Oct 8, 2013||Biogen Idec Ma Inc.||SP35 antibodies and uses thereof|
|US8569462||Jun 1, 2012||Oct 29, 2013||Xoma Technology Ltd.||Antibodies specific for TGF-beta and methods for treating thereof|
|US8586716||Aug 3, 2007||Nov 19, 2013||Novartis Ag||EPHB3-specific antibody and uses thereof|
|US8591886||Jul 11, 2008||Nov 26, 2013||Gitr, Inc.||Combination therapies employing GITR binding molecules|
|US8609407||Jan 23, 2012||Dec 17, 2013||Biogen Idec Ma Inc.||Sp35 antibodies and uses thereof|
|US8614103||Oct 26, 2007||Dec 24, 2013||Lpath, Inc.||Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions|
|US8629250||Jan 30, 2008||Jan 14, 2014||Amgen Inc.||Hepcidin, hepcidin antagonists and methods of use|
|US8652469||Jul 27, 2006||Feb 18, 2014||Novartis Ag||M-CSF-specific monoclonal antibody and uses thereof|
|US8765662||Mar 7, 2012||Jul 1, 2014||Biogen Idec Ma Inc.||NOGO receptor binding protein|
|US8852906||Jan 25, 2012||Oct 7, 2014||Tmo Renewables Limited||Thermophilic micro-organisms for ethanol production|
|US8871202||Sep 27, 2011||Oct 28, 2014||Lpath, Inc.||Prevention and treatment of pain using antibodies to sphingosine-1-phosphate|
|US8871720||Jul 7, 2006||Oct 28, 2014||Seattle Genetics, Inc.||Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus|
|US8901281||Jun 19, 2006||Dec 2, 2014||Merck Sharp & Dohme Corp.||ILT3 binding molecules and uses therefor|
|US8932821||Mar 14, 2013||Jan 13, 2015||Biogen Idec Ma Inc.||NOGO receptor binding protein|
|US8932841||Sep 28, 2007||Jan 13, 2015||Tmo Renewables Limited||Thermophilic microorganisms for ethanol production|
|US8940302||Oct 9, 2012||Jan 27, 2015||Genentech, Inc.||Predicting response to a HER inhibitor|
|US8999654||Oct 29, 2010||Apr 7, 2015||Omeros Corporation||Method of identifying a compound for the treatment or prevention of obesity|
|US9005614||Nov 22, 2010||Apr 14, 2015||Novartis Ag||PRLR-specific antibody and uses thereof|
|US9006398||Oct 16, 2013||Apr 14, 2015||Novartis Ag||EPHB3-specific antibody and uses thereof|
|US9028823||Mar 1, 2013||May 12, 2015||Gitr, Inc.||Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies|
|US9044461||Aug 14, 2013||Jun 2, 2015||The Research Foundation Of State University Of New York||Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency|
|US9066984||Mar 15, 2013||Jun 30, 2015||Biogen Ma Inc.||Sp35 antibodies and uses thereof|
|US9068992||Mar 13, 2013||Jun 30, 2015||Biogen Ma Inc.||Screening methods for identifying Sp35 antagonists|
|US9120858||Jul 20, 2012||Sep 1, 2015||The Research Foundation Of State University Of New York||Antibodies to the B12-transcobalamin receptor|
|US9145458||Sep 26, 2013||Sep 29, 2015||Xoma Technology Ltd.||Antibodies specific for TGF-β and methods of treatment thereof|
|US9155762||Oct 30, 2008||Oct 13, 2015||University Of Louisville Research Foundation, Inc.||Uses and isolation of stem cells from bone marrow|
|US9163091||Mar 18, 2009||Oct 20, 2015||Lpath, Inc.||Compositions and methods for binding lysophosphatidic acid|
|US9175078||Jan 23, 2009||Nov 3, 2015||Amgen Inc.||Ferroportin antibodies and methods of use|
|US9241992||Nov 15, 2013||Jan 26, 2016||Gitr, Inc.||Combination therapies employing GITR binding molecules|
|US9260521||Oct 3, 2013||Feb 16, 2016||Medigene Ag||Treatment of tumors using specific anti-L1 antibody|
|US20020108136 *||Aug 9, 2001||Aug 8, 2002||Sri||Transgenic animals produced by homologous sequence targeting|
|US20020132340 *||Mar 7, 2002||Sep 19, 2002||Todd Waldman||Isogenic beta-catenin cell lines, and methods of making and using same|
|US20030003097 *||Apr 2, 2002||Jan 2, 2003||Idec Pharmaceutical Corporation||Recombinant antibodies coexpressed with GnTIII|
|US20040203153 *||Feb 4, 2004||Oct 14, 2004||Institut Pasteur||Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made|
|US20040229310 *||Jan 23, 2004||Nov 18, 2004||Genentech, Inc.||Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture|
|US20040250301 *||Aug 13, 2003||Dec 9, 2004||Institut Pasteur||Transgenic animals|
|US20050239700 *||Oct 14, 2004||Oct 27, 2005||Biogen Idec Inc.||Treatment of cancer using antibodies to LRRC15|
|US20050287581 *||Aug 4, 2005||Dec 29, 2005||John Clark||Gene sequence of alpha(1,3)galactosyltransferase|
|US20060002930 *||Apr 15, 2005||Jan 5, 2006||Genentech, Inc.||Treatment of disorders|
|US20060009388 *||Jun 24, 2005||Jan 12, 2006||Sha Mi||Treatment of conditions involving demyelination|
|US20060015955 *||Aug 4, 2005||Jan 19, 2006||John Clark||Alpha(1,3)Galactosyltransferase enzyme that assembles the Galalpha(1,3)Gal xenoantigen|
|US20060063187 *||Sep 15, 2005||Mar 23, 2006||Hotamisligil Gokhan S||Modulation of XBP-1 activity for treatment of metabolic disorders|
|US20060275284 *||Aug 14, 2006||Dec 7, 2006||Biogen Idec Inc.||Combination therapy for treatment of autoimmune diseases using b-cell depleting/immunoregulatory antibody combination|
|US20070003544 *||Aug 14, 2006||Jan 4, 2007||Biogen Idec Inc.||Combination therapy for treatment of autoimmune diseases using b- cell depleting/immunoregulatory antibody combination|
|US20070041982 *||Jun 19, 2006||Feb 22, 2007||Tolerrx, Inc.||ILT3 binding molecules and uses therefor|
|US20070059793 *||Mar 17, 2004||Mar 15, 2007||Biogen Idec Ma Inc.||Nogo receptor binding protein|
|US20070092505 *||Oct 20, 2006||Apr 26, 2007||Roland Buelow||Production of humanized antibodies in transgenic animals|
|US20070098719 *||Mar 27, 2006||May 3, 2007||Tolerrx, Inc.||GITR binding molecules and uses therefor|
|US20070225244 *||May 10, 2007||Sep 27, 2007||Yakubov Leonid A||Compositions comprising genome segments and methods of using the same|
|US20070243616 *||May 16, 2007||Oct 18, 2007||President And Fellows Of Harvard College||In vivo alteration of cellular dna|
|US20080038260 *||Jun 19, 2007||Feb 14, 2008||Tolerrx, Inc.||ILT3 binding molecules and uses therefor|
|US20080171344 *||Dec 21, 2007||Jul 17, 2008||Kapsner Kenneth P||Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase|
|US20080182331 *||Mar 13, 2007||Jul 31, 2008||Institut Pasteur||Procedure for specific replacement of a copy of a gene present in the recipient genome by the integration of a gene different from that where the integration is made|
|US20080187966 *||Oct 30, 2007||Aug 7, 2008||Genentech, Inc.||Antibodies and methods for making and using them|
|US20080233118 *||Jul 27, 2006||Sep 25, 2008||Novartis Ag||Uses Of Antibody To M-Csf|
|US20080267974 *||Apr 9, 2008||Oct 30, 2008||Vaccinex, Inc.||Selection of Human TNFAlpha Specific Antibodies|
|US20090042265 *||May 3, 2006||Feb 12, 2009||Anthony Atkinson||Thermophilic Microorganisms with Inactivated Lactate Dehydrogenase Gene (LDH) for Ethanol Production|
|US20090074789 *||Oct 26, 2007||Mar 19, 2009||Sabbadini Roger A||Compositions and methods for treating ocular diseases and conditions|
|US20090111756 *||Jul 7, 2006||Apr 30, 2009||Seattle Genectics, Inc.||Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus|
|US20090130099 *||Oct 24, 2008||May 21, 2009||David Williams||Humanized antibodies and compositions for binding sphingosine-1-phosphate|
|US20090130712 *||Nov 21, 2006||May 21, 2009||Mckenna Sean D||Compositions and Methods of Producing Hybrid Antigen Binding Molecules and Uses Thereof|
|US20090136483 *||May 29, 2008||May 28, 2009||Sabbadini Roger A||Compositions and Methods for Binding Lysophosphatidic Acid|
|US20090136494 *||Jul 11, 2008||May 28, 2009||Tolerx, Inc.||Combination therapies employing GITR binding molecules|
|US20090142261 *||Aug 3, 2007||Jun 4, 2009||Novartis Ag||EPHB3-Specific Antibody and Uses Thereof|
|US20090155225 *||Oct 30, 2008||Jun 18, 2009||Mariusz Ratajczak||Uses and isolation of very small of embryonic-like (vsel) stem cells|
|US20090162355 *||Jun 13, 2008||Jun 25, 2009||Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts||Treatment of tumors using specific anti-l1 antibody|
|US20090178153 *||Oct 1, 2008||Jul 9, 2009||Omeros Corporation||G protein coupled receptors and uses thereof|
|US20090186034 *||Jul 23, 2009||Genetech, Inc.||Gene expression markers for inflammatory bowel disease|
|US20090197314 *||Jun 7, 2006||Aug 6, 2009||Anthony Atkinson||Modified Microorganisms with Inactivated Lactate Dehydrogenase Gene|
|US20100015131 *||Jul 9, 2009||Jan 21, 2010||Biogen Idec Ma Inc.||Composition Comprising Antibodies to LINGO or Fragments Thereof|
|US20100034814 *||Mar 18, 2009||Feb 11, 2010||Sabbadini Roger A||Compositions and methods for binding lysophosphatidic acid|
|US20100061974 *||Apr 5, 2007||Mar 11, 2010||Quadros Edward V||Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency|
|US20100092464 *||Jul 27, 2006||Apr 15, 2010||Novartis Ag||M-CSF-Specific Monoclonal Antibody and Uses Thereof|
|US20100173373 *||Sep 28, 2007||Jul 8, 2010||Tmo Renewables Limited||Thermophilic microorganisms for ethanol production|
|US20100226916 *||Oct 26, 2007||Sep 9, 2010||Sabbadini Roger A||Compositions and methods for treating ocular diseases and conditions|
|US20100267107 *||Sep 30, 2009||Oct 21, 2010||University Of Louisville Research Foundation, Inc.||Methods for isolating very small embryonic-like (vsel) stem cells|
|US20110034675 *||Feb 10, 2011||Tolerx, Inc.||Ilt3 Binding Molecules And Uses Therefor|
|US20110044990 *||Feb 24, 2011||Sabbadini Roger A||Antibody design using anti-lipid antibody crystal structures|
|US20110118443 *||May 19, 2011||Sabbadini Roger A||Antibody design using anti-lipid antibody crystal structures|
|US20110142836 *||Jun 16, 2011||Olav Mella||B-cell depleting agents for the treatment of chronic fatigue syndrome|
|US20110150760 *||Nov 22, 2010||Jun 23, 2011||Novartis Ag||PRLR-Specific Antibody and Uses Thereof|
|US20110171290 *||Apr 16, 2009||Jul 14, 2011||Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts||Inhibition of angiogenesis and tumor metastasis|
|US20110185439 *||Jul 28, 2011||Omeros Corporation||G protein coupled receptors and uses thereof|
|US20110189136 *||Oct 30, 2008||Aug 4, 2011||Mariusz Ratajczak||Uses and isolation of very small embryonic-like (vsel) stem cells|
|US20110214189 *||Sep 1, 2011||Omeros Corporation||G protein coupled receptors and uses thereof|
|US20110217760 *||Nov 5, 2009||Sep 8, 2011||TMO Renewables, Limited||Sporulation-deficient thermophilic microorganisms for the production of ethanol|
|EP1650220A2||Apr 3, 1998||Apr 26, 2006||Genentech, Inc.||Anti-VEGF antibodies|
|EP1916303A1||Nov 30, 2001||Apr 30, 2008||Medarex, Inc.||Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice|
|EP2014303A2||Jul 27, 2001||Jan 14, 2009||Genentech, Inc.||APO-2L receptor agonist and CPT-11 synergism|
|EP2052742A1||Jun 14, 2001||Apr 29, 2009||Biogen Idec Inc.||Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination|
|EP2062916A2||Apr 6, 2004||May 27, 2009||Genentech, Inc.||Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor|
|EP2067486A1||Jan 31, 2002||Jun 10, 2009||Biogen Idec Inc.||Use of CD23 antagonists for the treatment of neoplastic disorders|
|EP2077281A1||Jan 2, 2008||Jul 8, 2009||Bergen Teknologioverforing AS||Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome|
|EP2112167A2||Jun 23, 2000||Oct 28, 2009||Genentech, Inc.||Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies|
|EP2213302A2||May 25, 2000||Aug 4, 2010||Genentech, Inc.||DR4 antibodies and uses thereof|
|EP2233149A1||Oct 16, 2008||Sep 29, 2010||ZymoGenetics, Inc.||Combination of BLYS inhibition and anti-CD20 agents for treatment of autoimmune disease|
|EP2238986A2||Jul 7, 2006||Oct 13, 2010||Biogen Idec MA Inc.||Sp35 antibodies and uses thereof|
|EP2246363A1||Nov 17, 2003||Nov 3, 2010||Novartis Vaccines and Diagnostics, Inc.||Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis|
|EP2260858A2||Nov 5, 2004||Dec 15, 2010||Seattle Genetics, Inc.||Monomethylvaline compounds capable of conjugation to ligands|
|EP2261254A2||Dec 19, 2008||Dec 15, 2010||Amgen, Inc||Anti-amyloid antibodies and uses thereof|
|EP2261367A2||Nov 26, 2008||Dec 15, 2010||Genentech, Inc.||Gene expression markers for inflammatory bowel disease|
|EP2263691A1||Jul 11, 2003||Dec 22, 2010||Genentech, Inc.||Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)|
|EP2283866A2||Jun 23, 2000||Feb 16, 2011||Genentech, Inc.||Methods of treatment using anti-ERBB antibody-maytansinoid conjugates|
|EP2283867A2||Jun 23, 2000||Feb 16, 2011||Genentech, Inc.||Methods of treatment using anti-ERBB antibody-maytansinoid conjugates|
|EP2287192A1||Nov 17, 2003||Feb 23, 2011||Novartis Vaccines and Diagnostics, Inc.||Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis|
|EP2289942A2||Apr 9, 2003||Mar 2, 2011||Genentech, Inc.||Anti-HER2 antibody variants|
|EP2301580A1||Apr 3, 1998||Mar 30, 2011||Genentech, Inc.||Anti-VEGF antibodies|
|EP2311873A1||Jan 6, 2005||Apr 20, 2011||Novartis Vaccines and Diagnostics, Inc.||M-CSF-specific monoclonal antibody and uses thereof|
|EP2311880A2||Jan 5, 2006||Apr 20, 2011||Biogen Idec MA Inc.||Cripto binding molecules|
|EP2311881A2||Jan 5, 2006||Apr 20, 2011||Biogen Idec MA Inc.||Cripto binding molecules|
|EP2314318A1||Jan 31, 2002||Apr 27, 2011||Biogen Idec Inc.||CD80 antibody for use in combination with chemotherapeutics to treat B cell malignancies|
|EP2329714A1||Aug 3, 2005||Jun 8, 2011||Biogen Idec MA Inc.||Influence of TAJ in the neuronal functions|
|EP2336190A2||Apr 3, 1998||Jun 22, 2011||Genentech, Inc.||Anti-VEGF antibodies|
|EP2338915A2||Apr 3, 1998||Jun 29, 2011||Genentech, Inc.||Anti-VEGF antibodies|
|EP2343320A1||Mar 27, 2006||Jul 13, 2011||Tolerx, Inc.||GITR binding molecules and uses therefor|
|EP2371388A2||Oct 19, 2005||Oct 5, 2011||Genentech, Inc.||Antibody formulations|
|EP2385069A2||Nov 12, 2004||Nov 9, 2011||Biogen Idec MA Inc.||Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto|
|EP2389946A1||Mar 22, 2007||Nov 30, 2011||Novartis AG||Anti-tumor cell antigen antibody therapeutics|
|EP2389947A1||Mar 22, 2007||Nov 30, 2011||Novartis AG||Anti-tumor cell antigen antibody therapeutics|
|EP2389948A1||Mar 22, 2007||Nov 30, 2011||Novartis AG||Anti-tumor cell antigen antibody therapeutics|
|EP2389949A1||Mar 22, 2007||Nov 30, 2011||Novartis AG||Anti-tumor cell antigen antibody therapeutics|
|EP2389950A1||Mar 22, 2007||Nov 30, 2011||Novartis AG||Anti-tumor cell antigen antibody therapeutics|
|EP2389951A1||Mar 22, 2007||Nov 30, 2011||Novartis AG||Anti-tumor cell antigen antibody therapeutics|
|EP2394661A1||Jul 7, 2006||Dec 14, 2011||Biogen Idec MA Inc.||Sp35 antibodies and uses thereof|
|EP2423231A2||Aug 17, 2007||Feb 29, 2012||Novartis AG||PRLR-specific antibody and uses thereof|
|EP2423332A1||Aug 23, 2007||Feb 29, 2012||Oncotherapy Science, Inc.||Prognostic markers and therapeutic targets for lung cancer|
|EP2423333A1||Aug 23, 2007||Feb 29, 2012||Oncotherapy Science, Inc.||Prognostic markers and therapeutic targets for lung cancer|
|EP2474317A1||Jun 24, 2005||Jul 11, 2012||Biogen Idec MA Inc.||Treatment of conditions involving demyelination|
|EP2478912A1||Nov 5, 2004||Jul 25, 2012||Seattle Genetics, Inc.||Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy|
|EP2478917A1||Jul 7, 2006||Jul 25, 2012||Biogen Idec MA Inc.||SP35 antibodies and uses thereof|
|EP2481753A1||Dec 5, 2006||Aug 1, 2012||Eli Lilly and Company||Anti-IL-17 Antibodies|
|EP2486933A1||Nov 5, 2004||Aug 15, 2012||Seattle Genetics, Inc.||Monomethylvaline compounds conjugated with antibodies|
|EP2494988A1||Dec 6, 2007||Sep 5, 2012||Novartis AG||Antagonist antibodies against EPHB3|
|EP2510934A1||Nov 3, 2006||Oct 17, 2012||Biogen Idec MA Inc.||Methods for promoting neurite outgrowth and survival of dopaminergic neurons|
|EP2522678A1||May 15, 2007||Nov 14, 2012||Sea Lane Biotechnologies, LLC||Neutralizing antibodies to influenza viruses|
|EP2526968A2||Jan 26, 2007||Nov 28, 2012||Biogen Idec MA Inc.||Nogo receptor antagonists|
|EP2543384A2||Dec 1, 2006||Jan 9, 2013||Biogen Idec MA Inc.||Treatment of conditions involving demyelination|
|EP2551672A1||Sep 20, 2007||Jan 30, 2013||Nestec S.A.||Antibody-based arrays for detecting multiple signal transducers in rare circulating cells|
|EP2584049A2||Jul 19, 2010||Apr 24, 2013||Genentech, Inc.||Gene expression markers for Crohn's disease|
|EP2592156A2||Jun 4, 2008||May 15, 2013||Genentech, Inc.||Gene expression markers of tumor resistance to HER2 inhibitor treatment|
|EP2602623A2||Feb 24, 2009||Jun 12, 2013||Nestec S.A.||Mehtod for the detection of intracellular truncated receptors|
|EP2618146A2||Feb 24, 2009||Jul 24, 2013||Nestec S.A.||Drug selection for breast cancer therapy using antibody-based arrays|
|EP2620448A1||Apr 28, 2009||Jul 31, 2013||Amgen Inc.||Anti-hepcidin antibodies and methods of use|
|EP2633864A1||Jul 23, 2009||Sep 4, 2013||The Regents of the University of Colorado||Clip inhibitors and methods of modulating immune function|
|EP2644205A1||Apr 11, 2008||Oct 2, 2013||The Brigham and Women's Hospital, Inc.||Targeting ABCB5 for cancer therapy|
|EP2698380A1||Mar 27, 2009||Feb 19, 2014||Sea Lane Biotechnologies, LLC||Neutralizing molecules to viral antigens|
|EP2722051A1||Jul 7, 2006||Apr 23, 2014||Seattle Genetics, Inc.||Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus|
|EP2740744A2||Jan 9, 2008||Jun 11, 2014||Biogen Idec MA Inc.||SP35 antibodies and uses thereof|
|EP2757160A2||Jul 19, 2010||Jul 23, 2014||Genentech, Inc.||Gene expression markers for Crohn's disease|
|EP2787007A2||Nov 7, 2011||Oct 8, 2014||F. Hoffmann-La Roche AG||Subcutaneously administered ANTI-IL-6 receptor antibody|
|EP2803367A1||Jun 23, 2000||Nov 19, 2014||ImmunoGen, Inc.||Methods of treatment using anti-ERBB antibody-maytansinoid conjugates|
|EP2803675A2||Jan 23, 2009||Nov 19, 2014||Amgen, Inc||Ferroportin antibodies and methods of use|
|EP2816058A1||Oct 5, 2006||Dec 24, 2014||Eli Lilly and Company||Anti-myostatin antibodies|
|EP2816059A1||Apr 28, 2009||Dec 24, 2014||Amgen, Inc||Anti-hepcidin antibodies and methods of use|
|EP2851373A1||Dec 18, 2008||Mar 25, 2015||Xoma (Us) Llc||Methods for the treatment of gout|
|EP2857516A1||Mar 20, 2001||Apr 8, 2015||Genentech, Inc.||Multivalent antibodies and uses therefor|
|EP2899541A1||Feb 29, 2008||Jul 29, 2015||Genentech, Inc.||Predicting response to a HER dimerisation inhbitor based on low HER3 expression|
|EP2957296A1||Sep 25, 2010||Dec 23, 2015||Xoma (Us) Llc||Insulin receptor binding antibodies|
|EP2977063A1||Jun 23, 2000||Jan 27, 2016||Genentech, Inc.||Methods of treatment using anti-ErbB antibody-maytansinoid conjugates|
|EP2982695A1||Jul 9, 2009||Feb 10, 2016||Biogen MA Inc.||Compositions comprising antibodies to lingo or fragments thereof|
|WO2000075348A1||Jun 8, 2000||Dec 14, 2000||Seattle Genetics, Inc.||Recombinant anti-cd40 antibody and uses thereof|
|WO2007067280A2 *||Nov 2, 2006||Jun 14, 2007||University Of Louisville Research Foundation, Inc.||Very small embryonic-like (vsel) stem cells and methods of isolating and using the same|
|WO2007067280A3 *||Nov 2, 2006||Apr 30, 2009||Magdalena Kucia||Very small embryonic-like (vsel) stem cells and methods of isolating and using the same|
|WO2007070750A1||Dec 5, 2006||Jun 21, 2007||Eli Lilly And Company||Anti-il-17 antibodies|
|WO2008055072A2||Oct 26, 2007||May 8, 2008||Lpath, Inc.||Compositions and methods for treating ocular diseases and conditions|
|WO2008070344A2||Oct 26, 2007||Jun 12, 2008||Lpath, Inc.||Compositions and methods for binding sphingosine-1-phosphate|
|WO2009028580A1||Aug 21, 2008||Mar 5, 2009||Oncotherapy Science, Inc.||Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis|
|WO2009085200A2||Dec 19, 2008||Jul 9, 2009||Amgen Inc.||Anti-amyloid antibodies and uses thereof|
|WO2009086003A1||Dec 18, 2008||Jul 9, 2009||Xoma Technology Ltd.||Methods for the treatment of gout|
|WO2009139822A1||Apr 28, 2009||Nov 19, 2009||Amgen Inc.||Anti-hepcidin antibodies and methods of use|
|WO2010078526A1||Dec 31, 2009||Jul 8, 2010||Biogen Idec Ma Inc.||Anti-lymphotoxin antibodies|
|WO2010080528A1||Dec 17, 2009||Jul 15, 2010||Genentech, Inc.||Hepatitis c virus combination therapy|
|WO2010111180A1||Mar 22, 2010||Sep 30, 2010||Teva Biopharmaceuticals Usa, Inc.||Humanized antibodies against light and uses thereof|
|WO2011008990A1||Jul 15, 2010||Jan 20, 2011||Prometheus Laboratories Inc.||Drug selection for gastric cancer therapy using antibody-based arrays|
|WO2011011339A1||Jul 19, 2010||Jan 27, 2011||Genentech, Inc.||Gene expression markers for crohn's disease|
|WO2011038301A2||Sep 24, 2010||Mar 31, 2011||Xoma Technology Ltd.||Screening methods|
|WO2011038302A2||Sep 25, 2010||Mar 31, 2011||Xoma Technology Ltd.||Novel modulators|
|WO2011050069A1||Oct 20, 2010||Apr 28, 2011||Prometheus Laboratories Inc.||Proximity-mediated assays for detecting oncogenic fusion proteins|
|WO2011063277A1||Nov 19, 2010||May 26, 2011||Amgen Inc.||Anti-orai1 antigen binding proteins and uses thereof|
|WO2012006633A1||Jul 11, 2011||Jan 12, 2012||Biogen Idec Hemophilia Inc.||Chimeric clotting factors|
|WO2012021648A1||Aug 10, 2011||Feb 16, 2012||Amgen Inc.||Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies|
|WO2012040518A2||Sep 22, 2011||Mar 29, 2012||Amgen Inc.||Carrier immunoglobulins and uses thereof|
|WO2012064627A2||Nov 7, 2011||May 18, 2012||Genentech, Inc.||Subcutaneously administered anti-il-6 receptor antibody|
|WO2012071436A1||Nov 22, 2011||May 31, 2012||Genentech, Inc.||Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants|
|WO2012075037A1||Nov 29, 2011||Jun 7, 2012||Genentech, Inc.||Low affinity blood brain barrier receptor antibodies and uses therefor|
|WO2012075333A2||Dec 1, 2011||Jun 7, 2012||Prometheus Laboratories Inc.||Her2delta16 peptides|
|WO2012088337A1||Dec 21, 2011||Jun 28, 2012||Prometheus Laboratories Inc.||Drug selection for malignant cancer therapy using antibody-based arrays|
|WO2012099566A1||Nov 17, 2011||Jul 26, 2012||Sea Lane Biotechnologies, Llc||Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody|
|WO2012099983A1||Jan 18, 2012||Jul 26, 2012||Amgen Inc.||Nav1.7 knockout mice and uses thereof|
|WO2013012733A1||Jul 13, 2012||Jan 24, 2013||Biogen Idec Ma Inc.||Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto|
|WO2013033623A1||Aug 31, 2012||Mar 7, 2013||Nestec S.A.||Profiling of signal pathway proteins to determine therapeutic efficacy|
|WO2013096516A1||Dec 19, 2012||Jun 27, 2013||Xoma Technology Ltd.||Methods for treating acne|
|WO2013101771A2||Dec 21, 2012||Jul 4, 2013||Genentech, Inc.||Compositions and method for treating autoimmune diseases|
|WO2013106577A2||Jan 10, 2013||Jul 18, 2013||Biogen Idec Ma Inc.||Enhancement of transport of therapeutic molecules across the blood brain barrier|
|WO2013126813A1||Feb 22, 2013||Aug 29, 2013||Amgen Inc.||Autologous mammalian models derived from induced pluripotent stem cells and related methods|
|WO2013173687A1||May 17, 2013||Nov 21, 2013||Genentech, Inc.||High-concentration monoclonal antibody formulations|
|WO2013177062A2||May 20, 2013||Nov 28, 2013||Genentech, Inc.||Methods for improving safety of blood-brain barrier transport|
|WO2014033074A1||Aug 26, 2013||Mar 6, 2014||F. Hoffmann-La Roche Ag||Blood brain barrier shuttle|
|WO2015023596A1||Aug 11, 2014||Feb 19, 2015||Genentech, Inc.||Compositions and method for treating complement-associated conditions|
|WO2015035332A1||Sep 8, 2014||Mar 12, 2015||Canimguide Therapeutics Ab||Immune system modulators|
|U.S. Classification||435/6.16, 435/463|
|International Classification||C12N15/90, A01K67/027, C12N15/85, C12N5/10, A61K48/00, C12N15/09, C12N15/65|
|Cooperative Classification||A01K2267/03, A01K2227/105, C12N15/907, C12N15/65, C12N15/85, A01K2217/075, A61K48/00, A01K67/0276, C12N15/8509|
|European Classification||C12N15/85A, A01K67/027M2, C12N15/85, C12N15/65, C12N15/90B4|
|May 8, 2000||FPAY||Fee payment|
Year of fee payment: 4
|Jun 30, 2004||FPAY||Fee payment|
Year of fee payment: 8
|Aug 17, 2005||AS||Assignment|
Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, MASSACHU
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MORTENSEN, RICHARD M.;REEL/FRAME:016641/0513
Effective date: 20050718
|May 16, 2006||CC||Certificate of correction|
|Jun 30, 2008||FPAY||Fee payment|
Year of fee payment: 12
|Jul 7, 2008||REMI||Maintenance fee reminder mailed|